| Revenue growth | FY26 Revenue: INR 647.6 mn (down 7.6% YoY) |
|---|---|
| Margins | EBITDA down 8.1% in FY26; Q4 EBITDA down 45.6% |
| Demand visibility | Strong export focus (~75% revenue share) |
Growth
Q4 revenue down 42.2%, PAT down 57.2% YoY. FY26 revenue fell 7.6%, PAT dropped 14.6% YoY.
Outlook
Ongoing expansion with new plants in Prague and Pune (2025). Expanding into high-margin IV infusions.
Risks
Substantial year-on-year declines in revenue and profitability across all primary standalone metrics during FY26.
Earnings Call filed with BSE, NSE: SANJIVIN. Summary written with AI assistance from the document.
Sanjivani Paranteral Ltd: key numbers
- Share price
- ₹169.05
- Market cap
- ₹207.7 Cr
- Revenue (annual)
- ₹68.67 Cr
- Net profit (annual)
- ₹6.79 Cr
- P/E (TTM)
- 19.7×Sector 50.4×
- Promoter holding
- 31.56%+0.30% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanjivani Paranteral Ltd
All →Sanjivani Paranteral Fund Raise
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Investor Presentation: Key Takeaways
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
- Call
- Guides 110% growth
Sanjivani Paranteral Q1 FY27 Results: Net Profit ₹2.5 Cr, Up 47.1% YoY
Sanjivani Paranteral Ltd reported revenue from operations of ₹23.8 Cr (+33.0% YoY) and net profit of ₹2.5 Cr (+47.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹2.5 Cr · +47.1% YoY
Sanjivani Paranteral Earnings Call: Key Takeaways
Sanjivani Paranteral Q4 FY26 earnings transcript. Management transitions to a multi-vertical platform with base formulation business and new IVF and nutraceutical ventures.
Sanjivani Paranteral Q4 FY26 Results: Net Profit ₹0.5 Cr, Down 77.3% YoY
Sanjivani Paranteral Ltd reported revenue from operations of ₹13.2 Cr (-27.5% YoY) and net profit of ₹0.5 Cr (-77.3% YoY) for Q4 FY26.
- Key figure
- Net profit ₹0.5 Cr · -77.3% YoY